Type II hereditary angioedema: presentation and follow-up of three cases.

Abstract

Three cases with a family history of type II hereditary angioedema (HAE) are presented, together with their progress following treatment with stanozolol. The development of patients with this drug was satisfactory in clinical terms, as it gave rise to virtually no side effects or angioedema episodes. Only patient 3 showed an elevation of hepatic enzyme (SGOT, SGPT) levels in serum, 2 months after starting treatment. C4 values of patient 2 attained sporadic normalization in the first five months of treatment, while the values corresponding to the other two patients remained below normal at all times. The activity of C1 inhibitor (C1-INH) remained below normal in all three cases. In patient 3, it was observed that circulating immunocomplex (CIC) monitoring was, together with clinical progress, a useful method for controlling HAE activity.

• Authors: J Arias, A Moral, M A García, M Fernández-Rivas, R Abengózar, P Panadero, C Senent
• Journal: Allergologia et immunopathologia (Allergol Immunopathol (Madr)) 1994 Nov-Dec Vol. 22 Issue 6 Pg. 244-9 ISSN: 0301-0546 [Print] Singapore
• PMID: 7892812 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antifibrinolytic Agents
• Antigen-Antibody Complex
• Complement C1 Inactivator Proteins
• Complement C2
• Complement C4
• Stanozolol
• Tranexamic Acid
• Aspartate Aminotransferases
• Alanine Transaminase
• Creatine Kinase

Topics

• Adolescent
• Adult
• Alanine Transaminase (blood)
• Angioedema (classification, drug therapy, enzymology, genetics)
• Antifibrinolytic Agents (therapeutic use)
• Antigen-Antibody Complex (blood)
• Aspartate Aminotransferases (blood)
• Complement C1 Inactivator Proteins (deficiency)
• Complement C2 (deficiency)
• Complement C4 (deficiency)
• Creatine Kinase (blood)
• Drug Therapy, Combination
• Female
• Follow-Up Studies
• Humans
• Male
• Pedigree
• Stanozolol (therapeutic use)
• Tranexamic Acid (therapeutic use)